Project Description

Mucosat (10% solution of chondroitin sulfate for injections)

international nonproprietary name

Chondroitin sulfate.

Ref

BP-0086

Pharmacotherapeutic group

Metabolism compensator of bone and  cartilage tissue.

Composition of the preparation

1 ml of solution for injections contains 100 mg of chondroitin sulfate.

Pharmacological action

Pharmacodynamics

Main active agents of preparation are sodium salts of chondroitin sulfate A and C (average molecular weight is 11000 daltons). Chondroitin sulfate is high-molecular mucopolysaccharide. It is the basic component of proteoglycans, making together with collagenous fibers cartilaginous matrix.

The preparation inhibits the process of degeneration and stimulates regeneration of cartilage tissue, have hondroprotective, antiinflammatory, analgesic effect. It replaces chondroitin sulfate of articular cartilage, catabolised with pathologic process. It suppresses activity of enzymes bringing on degradation of articular cartilage: inhibits metalloproteinases, especially leukocytic elastase. It lowers activity of hyaluronidase, partially blocks emission of free oxygen radicals; promotes blocking of chemotaxis, antigenic determinants. It stimulates generation of proteoglycans by chondrocites. It influences phosphoric- potassium metabolism in cartilage tissue. It permits to restore mechanical and elastic consistency of cartilaginous matrix. Anti-inflammatory and analgesic effects are achieved due to resolution of release into synovial fluid of inflammation mediators and pain factors through syniviacites and macrophages of synovial membrane as well as owing to inhibiting secretion of leukotriene B4 and prostaglandin E2.

Application of the preparation enables to restoration of articular bursa and articular cartilage surface, prevents from constriction of connective tissue, performs the role of  lubrication for articular surfaces, normalizes production of glenoid fluid, improves mobility of joints, promotes to reduction of pain intensity, improves quality of life.

Chondroitin sulfate retards resorption of bone tissue and relieves the loss of calcium, accelerates  mobilization processes of bone tissue.

Pharmacokinetics

After intramuscular introduction chondroitin sulfate penetrates into synovial fluid. Maximum concentration in synovial fluid is achieved in 4-5 hours after injection. It is excreted from organism within 24 hours. It is predominantly eliminated by kidneys.

Indications 

Degenerative diseases of joints and spinal column: primary arthrosis, intervertebral osteochondrosis.

special indication

To achieve stable clinical effect there is required minimum 25 injections of chondroitin sulfate, but the effect is preserved for a long time within many months after termination of the course of treatment.

special warning

Treatment cessation at allergic reactions or hemorrhages.

Dosage and method of administration

The preparation is introduced intramuscularly in a dose of 1 ml every other day. Provided good tolerance dose is increased to 2 ml starting from the fourth injection. Course of treatment is 25-35 injections. Refresher course of treatment is prescribed in 6 months.

Prescription of preparation to children is solved by a doctor individually depending on clinical situation.

overdosage

Not established

safety measures

Not established

Side effects

At preparation intake allergic reactions, hemorrhages are possible in the site of injection.

Contraindications

Increased individual sensitivity to any of the components of the preparation, susceptibility to bleeding sickness, thrombophlebitis, pregnancy, lactation (treatment cessation during breast-feeding ).

Interactions with other medicinal preparations

In combination with nonsteroidal anti-inflammatory drugs chondroitin sulfate allows to lower  dosage of nonsteroidal anti-inflammatory drugs.

The form of release

10% solution for injections in ampuls containing 1 and 2 ml. 5 ampuls inserted into contour cellular pack.